THE COMPARISON
Beyond the weight-loss percentages
Two metabolic compounds. Different mechanisms. Different experiences. What does the evidence actually tell us?
Tirzepatide and retatrutide act on hormone receptors involved in appetite, blood glucose, and body-weight regulation, but they do not activate exactly the same pathways. Both have produced substantial average weight reductions in clinical studies, although separate trials cannot tell us which works better in the same population.
This guide separates three kinds of information: published clinical research, company-reported trial results, and unverified personal accounts. They can answer different questions, but they do not carry the same weight.
UNDERSTANDING THE SCIENCE
How they work
A receptor is a protein that receives a biological signal. An “agonist” activates that receptor; these compounds target receptors for hormones that help coordinate metabolism.
CLINICAL RESULTS
What the trials reveal about weight loss
Clinical trials use defined participant groups and measured outcomes, which makes them more useful for evaluating a treatment than isolated testimonials. The results below come from separate obesity trials in adults without diabetes.
Why the analysis matters
A treatment-regimen analysis estimates outcomes regardless of whether participants stopped the assigned treatment, while an efficacy analysis asks what outcomes would look like if treatment were taken as intended. In the same TRIUMPH-1 report, the 12 mg result was 25.0% under the treatment-regimen analysis, compared with 28.3% under the efficacy analysis.
Participants, follow-up times, and statistical methods differ across these studies, so the percentages are not a fair “winner” ranking. A direct retatrutide-versus-tirzepatide study, TRIUMPH-5, is registered, with no results posted in the registry at this article’s review.
Tirzepatide’s approved prescribing information draws on multiple clinical trials; retatrutide’s published Phase 2 work and company-reported Phase 3 results show substantial weight reductions, with further investigation continuing. The extra receptor target is a scientific difference, not proof that it alone explains the numerical difference between trials.
HUNGER, FULLNESS & CRAVINGS
Appetite and “food noise” are not the same thing
In everyday conversation, “food noise” describes persistent thoughts about food or cravings. Here, it is a plain-language description, not a diagnosis or a substitute for a measured clinical outcome.
What has been measured with tirzepatide?
A randomized six-week trial involving 114 adults found that tirzepatide reduced food intake compared with placebo, with reported improvements in appetite, hunger, cravings, and reactions to food cues. That study provides direct evidence about eating behavior, but it did not compare tirzepatide with retatrutide.
Why retatrutide accounts can sound different
Some online accounts describe weight loss alongside relatively little perceived appetite suppression, while describing earlier fullness or fewer cravings. Such accounts can help frame questions about lived experience, but cannot establish how common that response is or which compound provides stronger appetite control.
The useful distinction is simple: a change on the scale and a change in how eating feels are different measurements. Neither one should be used to fill in information that a study did not collect.
PERSONAL PERSPECTIVES
What individuals are reporting
These two publicly posted accounts are unverified personal reports, not Meridian customer testimonials or medical evidence. They illustrate questions worth asking, not results a reader should expect.
Weight change without strong appetite suppression
One commenter reported losing about 40 pounds while feeling relatively little appetite suppression, but said they felt full sooner and had fewer cravings (original discussion). The distinction in this account is between hunger, fullness, and cravings, rather than a single “appetite” score.
A positive report with several compounds involved
Another individual reported about 58 pounds of weight loss over seven months and attributed much of their progress to retatrutide, while also describing exposure to other compounds (original discussion). Because several substances were involved, the account cannot isolate what caused the reported change.
Neither account provides independently verified product identity, exposure, medical history, or measured follow-up. The linked discussions may contain advice beyond this article; including them is not an endorsement of that advice or of combining compounds.
TOLERABILITY & SAFETY
What clinical studies have observed
Digestive symptoms are common in the clinical data for both compounds, including nausea, diarrhea, vomiting, and constipation. Safety is more than a list of common symptoms: severity, reasons for stopping treatment, and longer-term follow-up also matter.
Tirzepatide
Common adverse reactions include nausea, diarrhea, vomiting, constipation, abdominal pain, and indigestion. Important warnings include pancreatitis, gallbladder disease, severe digestive reactions, kidney injury related to dehydration, serious allergic reactions, and low blood sugar, especially with certain other glucose-lowering medicines.
Tirzepatide carries a boxed warning about thyroid C-cell tumors seen in rodents; whether it causes these tumors in humans is unknown. The label contraindicates use in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
Retatrutide
Lilly reported the following common adverse events for the 12 mg group in TRIUMPH-1. These are percentages within that trial, not a comparison against tirzepatide.
The Phase 2 trial found dose-related increases in heart rate that peaked at 24 weeks and later declined. The Phase 3 report also described dysesthesia, meaning altered or uncomfortable skin sensations.
Retatrutide’s longer-term safety remains under investigation, and it has not received FDA approval. Percentages from unrelated trials should not be used to declare either compound easier to tolerate.
UNDERSTANDING VARIATION
Why results and experiences can differ
A trial average describes a group, not a promise to every participant. The individual response distributions in both published obesity trials show considerable variation.
THE EVIDENCE AT A GLANCE
What we know and what remains uncertain
COMMON QUESTIONS
Frequently asked questions
Which has produced greater weight reduction in clinical trials?
Selected retatrutide trial arms have reported numerically larger mean reductions, but the trials differ in duration, participants, and analysis; that is not proof of superiority.
Why do some people describe stronger appetite suppression with tirzepatide?
Individual reports cannot tell us whether that is typical. A tirzepatide study directly measured improvements in appetite and cravings, but did not compare it with retatrutide.
Can someone report weight loss while still feeling hungry?
Yes; one account linked here described weight loss with little perceived appetite suppression. That is an unverified report, not an estimate of how often this occurs.
Does retatrutide increase metabolism?
Its glucagon-receptor activity is linked to energy-expenditure biology, but how much that pathway contributes to human weight loss remains under investigation. “Increases metabolism” is too broad to describe a proven individual outcome.
Can weight loss slow down over time?
Weight trajectories can change over months rather than follow a constant weekly pace. A slowing trend alone cannot identify its cause.
Is retatrutide an FDA-approved alternative to tirzepatide?
No. Retatrutide remains investigational, while specific prescription products containing tirzepatide are FDA approved.
THE BOTTOM LINE
A useful comparison looks beyond the scale
Tirzepatide and retatrutide share two receptor targets, but retatrutide adds glucagon-receptor activity and remains investigational. Tirzepatide has an established approved-use evidence base, while retatrutide’s clinical program continues to develop.
The most useful questions are not simply “Which percentage is larger?” They are: What was measured? In whom? For how long? With which safety findings? Personal stories can make those questions more relatable, but controlled studies remain the better way to answer them.
READ THE RESEARCH
Scientific references
Tirzepatide Once Weekly for the Treatment of Obesity
Jastreboff and colleagues. NEJM. SURMOUNT-1 outcomes over 72 weeks.
Read the study → PHASE 2 HUMAN TRIAL · 2023Triple–Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial
Jastreboff and colleagues. NEJM. Weight and safety findings over 48 weeks.
Read the study → RANDOMIZED HUMAN TRIAL · 2025Tirzepatide on ingestive behavior in adults with overweight or obesity: a randomized 6-week phase 1 trial
Martin and colleagues. Nature Medicine. Food intake, appetite, and cravings.
Read the study → COMPANY TOPLINE REPORT · MAY 21, 2026Lilly’s triple agonist, retatrutide, delivered powerful weight loss in pivotal Phase 3 obesity trial
Lilly’s TRIUMPH-1 announcement, distinct from a peer-reviewed journal report.
Read the report → FDA PRESCRIBING INFORMATION · 2026Zepbound prescribing information
Approved indications, trial findings, contraindications, and safety warnings.
Read the label → CLINICAL TRIAL REGISTRY · NCT06662383Retatrutide compared to tirzepatide in adults who have obesity
The registered TRIUMPH-5 head-to-head study and its current results status.
View the trial →